CLINICAL NEWS
Brentuximab Vedotin Plus Nivolumab May Be an Alternative to Salvage
Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma
• 5 (8.3%) experienced progressive
disease
• 5 (8.3%) did not respond
Seventeen patients received subsequent
salvage therapy, most of whom received
ICE (ifosfamide, carboplatin, etoposide;
n=12). Response rates were similar in
this subset: overall response rate was 80
percent (95% CI 52-96), with a 40 percent
CR rate (95% CI 16-68).
At analysis, 54 patients had undergone
AHCT: 41 (76%) had CR, 11 (20%) had PR,
and one (2%) had stable disease (1 patient
was not evaluable). Most (n=42) were able
to proceed directly to AHCT after treatment
with brentuximab vedotin and nivolumab,
suggesting that “[this combination] is an
T:7”
S:6.75”
EXPLORE THE COVERAGE
OF KOVALTRY ®
Dosing with KOVALTRY ® for routine prophylaxis in adults 1 :
Individualize the patient’s dose based on clinical response
Dose Regimen
20–40 IU/kg 2x/week or 3x/week
LEOPOLD I trial: KOVALTRY ® PK results (arithmetic mean) 1
PK parameters were measured using chromogenic substrate assay after a single
50-IU/kg dose of KOVALTRY ® in 21 previously treated patients ≥18 years old
The AUC was 2103.4 IU•h/dL
The C max was 133.1 IU/dL
The t 1/2 was 14.2 hours
AUC=area under the curve.
C max =maximum concentration.
LEOPOLD=Long-Term Efficacy Open-Label
Program in Severe Hemophilia A Disease.
PK=pharmacokinetics.
t 1/2 =half-life.
See how KOVALTRY ®
compared with Advate ®
in a cross-over PK study
INDICATIONS
KOVALTRY ® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence
derived, full length Factor VIII concentrate indicated for use in adults and children with
hemophilia A for:
On-demand treatment and control of bleeding episodes
Perioperative management of bleeding
Routine prophylaxis to reduce the frequency of bleeding episodes
KOVALTRY ® is not indicated for the treatment of von Willebrand disease.
SELECTED IMPORTANT SAFETY INFORMATION
KOVALTRY ® is contraindicated in patients who have a history of hypersensitivity reactions
to the active substance, to any of the excipients, or to mouse or hamster proteins.
Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY ® . Early signs
of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat
tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY ® if symptoms
occur and seek immediate emergency treatment.
Please see additional Selected Important Safety Information on the following pages.
For additional risk and use information, please see Brief Summary on following pages.
ASHClinicalNews.org
• 37 (61.7%) experienced a complete
response (CR; primary endpoint)
• 13 (21.7%) experienced a partial
response (PR)
In a phase I/II study published in Blood,
the combination of brentuximab vedotin
plus nivolumab was an effective first salvage
therapy in patients with relapsed/refractory
Hodgkin lymphoma (HL), with 83 percent
of patients responding to treatment.
The response rates reported in this
study “are higher than those observed
with brentuximab vedotin or nivolumab
alone in relapsed/refractory HL and are
higher than with brentuximab vedotin
… as initial salvage therapy,” noted lead
author Alex F. Herrera, MD, from the
Department of Hematology/Hemato-
poietic Cell Transplantation at the City
of Hope Medical Center in Los Angeles,
California, and co-authors. The findings
suggest this combination could provide an
alternative to traditional chemotherapy.
The open-label, multicenter study
included adults who were eligible for
autologous hematopoietic cell trans-
plantations (AHCT), had disease that
relapsed or was refractory to standard
frontline chemotherapy, and had an
Eastern Cooperati